February 24, 2024
London, UK

Madrigal Pharmaceuticals (MDGL) Announces $300+ Million in Financing Events to Advance Resmetirom Program

MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (MDGL) announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit Facility.

Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated: “The financings secured following the positive topline readout of our Phase 3 MAESTRO-NASH trial reflect the strong support that Madrigal has established with long-standing strategic and institutional investors. The funds provide a solid foundation for the road ahead and will be used to support planned commercial and clinical activities through potential accelerated approval of resmetirom in the U.S.”

Madrigal has completed $159 million in gross sales of common stock under its ATM Program (“ATM Sales”) and has separately entered into a $100 million definitive securities purchase agreement with two of its existing institutional investors for the purchase of $90 million in shares of Series B Convertible Preferred Stock (the “Series B”) and $10 million in shares of the Company’s common stock (“Registered Direct Sales”).

The Registered Direct Sales were made to two long-standing institutional stockholders of Madrigal and is anticipated to close on or about December 23, 2022. The Series B is substantially identical to the Series A Convertible Preferred Stock issued by the Company in 2017, with the most significant difference being the current conversion price of $225 per common share. The total number of shares of common stock (including common stock equivalents) sold through the ATM Sales and the Registered Direct Sales totaled 1,183,344 common equivalent shares.

In connection with Madrigal’s December 19, 2022 announcement of positive topline data from its pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom, Hercules Capital, Inc. (HTGC) confirmed that Madrigal has achieved its clinical milestone under the Company’s Credit Facility with Hercules, thereby enabling MDGL to draw upon a $50 million clinical milestone tranche over the next three months.

Previous Article

Alphabet (GOOGL) Analysts Forecasts and Price Targets

Next Article

UK Ministry of Defence awards Palantir (PLTR) £75 million Enterprise Agreement

You might be interested in …

LVS Las Vegas Sands

Here is Why Las Vegas Sands Jumps Today

Las Vegas Sands Corporation (LVS) is trading 12.35% higher at $39.85 after Macao announced its plan to allow tour groups from mainland China starting in November after three years of restriction.